Assessing del(13q)/-13 in Multiple Myeloma
Mikulski DM, Marcoux C, Tanner MR, et al. Prognostic Impact of Monosomy 13 and Deletion of 13q in Multiple Myeloma Patients Undergoing Upfront Autologous Transplantation. British Journal of Haematology. 2026; (doi: 10.1111/bjh.70694).
Results from a retrospective investigation identified deletion (13q)/monosomy 13 (del[13q]/-13) as an independent risk factor for poor outcomes in multiple myeloma (MM) patients receiving upfront autologous hematopoietic stem cell transplantation (auto-HSCT). The single-site study included 1,680 patients who underwent auto-HSCT during 2010-2021, with del[13q]/-13 confirmed in 591. Progression-free survival (PFS) was 37.3 months for participants with isolated del[13q]/-13 compared with 64.6 months for participants without del[13q]/-13 or any established high-risk cytogenetic abnormalities (HRCA). Median overall survival (OS) in the two groups was 105.4 months and 131 months, respectively. Patients with concurrent HRCA and del[13q]/-13 had the poorest outcomes, according to the study authors. In this subpopulation, PFS reached just 33.9 months and OS was only 81.6 months.